Uppsala, Sweden – September 16, 2013 – Orexo AB (STO: ORX) announced today that a sponsored level 1 American Depositary Receipt (ADR) program in the United States has now been fully implemented and the ADRs can now be traded on the OTC market under the symbol ORXOY. Implementation of the ADR program coincides with the commercial launch of Zubsolv®, which is the company’s leading product for maintenance treatment of opioid dependence.
Help employers find you! Check out all the jobs and post your resume.
